For Slamon, who serves as director of clinical and translational research at the UCLA Health Jonsson Comprehensive Cancer Center and chief of hematology/oncology at the David Geffen School of Medicine at UCLA, the recognition arrives after more than four decades of work that fundamentally reorganized how oncologists think about tumors. In a statement accompanying the announcement, he emphasized the collective nature of the achievement. “I’m incredibly honored to receive the Albany Award, but I think the best award is the fact that we — and I say we because it was not just me alone, but a group of us working on this — saw that we made an impact on so many lives,” Slamon said.

The scientific insight at the heart of the award is deceptively simple in hindsight: cancers arising in the same organ are not necessarily the same disease. Before Slamon’s work, breast cancer was largely treated as a single entity, stratified mainly by how far it had spread and how the cells looked under a microscope. Slamon’s team helped establish that tumors in the same organ can be biologically distinct diseases, each propelled by different molecular changes. That reframing has since become one of the organizing principles of modern oncology, underpinning the entire field of precision medicine in cancer care.

The specific discovery that changed everything involved a gene called HER2, which plays a role in regulating cell growth. Slamon’s laboratory found that roughly 20 percent of breast cancers contained multiple copies of this gene, a genetic amplification that floods the cell with growth-signaling machinery. Patients whose tumors carried this alteration tended to have more aggressive disease and poorer outcomes, a correlation that at first seemed to make HER2 merely a grim prognostic marker. But Slamon and his colleagues pushed the analysis further, demonstrating that HER2 was not simply a passive flag of aggressive disease — it was actively helping to drive tumor growth. That distinction transformed HER2 from a statistical indicator into a therapeutic target.

Turning that target into a drug required persistence in the face of considerable skepticism. Slamon and his collaborators began testing antibodies designed to latch onto the HER2 protein on the surface of cancer cells, an approach that many in the field doubted because previous attempts to use antibodies against cancer had largely failed. The laboratory evidence, however, kept pointing in the same direction: blocking HER2 could inhibit tumor growth. Working with scientists at Genentech, the team moved the strategy into human testing, with Slamon leading the first clinical trials of the antibody that would become known as Herceptin, conducted at UCLA. Those early studies showed that targeting HER2 with an antibody could produce a genuine clinical effect, and subsequent randomized trials demonstrated that adding Herceptin to standard treatment significantly improved outcomes for patients with HER2-positive breast cancer.

In 1998, the U.S. Food and Drug Administration approved Herceptin, and the consequences for patients were profound. HER2-positive breast cancer, once among the most aggressive and feared forms of the disease, became one of the breast cancers that can most often be treated successfully. Approximately 3.5 million women worldwide have now been treated with Herceptin for breast cancer, a figure that captures the scale of the translation from a chromosome abnormality identified in a laboratory to a therapy deployed across the globe. The success also validated a principle that has since reshaped drug development across oncology: identify the specific molecular change driving a tumor, and design a treatment against it.

Slamon and his colleagues did not stop with HER2. Applying the same logic of molecular targeting to other subtypes of the disease, their research helped demonstrate the effectiveness of CDK4/6 inhibitors — including palbociclib and ribociclib, marketed commercially as Ibrance and Kisqali — in hormone receptor-positive breast cancer. This subtype is the most common form of the disease, accounting for approximately 65 to 70 percent of breast cancers globally, which means the impact of this second line of research reaches an even larger patient population than the first. CDK4/6 inhibitors work by interfering with the cellular machinery that drives proliferation, effectively braking the cell division cycle that tumors depend upon, and the class has now become part of the standard of care for ER-positive breast cancer.

The reach of the original HER2 discovery has continued to expand in ways that extend well beyond breast cancer. HER2-targeted therapies are now used to treat other cancers driven by the same molecular alteration, and a newer generation of drugs known as antibody-drug conjugates builds directly on the approach Slamon pioneered. These engineered molecules use antibodies as delivery vehicles, homing in on tumor cells and releasing cancer-killing payloads more precisely than conventional chemotherapy, thereby concentrating toxicity where it is needed and sparing healthy tissue. It is a striking example of how a single mechanistic insight can keep generating clinical dividends decades after the initial discovery.

Leaders at UCLA framed the award as a testament to the kind of research the prize is designed to celebrate. “Dennis’ work represents the very best of what we strive to do in cancer research, taking discoveries made in the laboratory and translating them into treatments that fundamentally change patients’ lives,” said Dr. Michael Teitell, director of the UCLA Health Jonsson Comprehensive Cancer Center. “His pioneering research not only transformed the treatment of breast cancer but helped change how we understand and treat cancer more broadly. This recognition is incredibly well deserved.” The Albany Prize’s emphasis on translation — on the difficult, often unglamorous passage from bench discovery to approved therapy — makes Slamon’s career an almost archetypal case study of what that process demands.

Slamon’s work is not finished. He continues to investigate new antibody-based therapies and treatment combinations aimed at improving cancer control while reducing treatment-related side effects and preserving patients’ quality of life, a focus that reflects how survivorship has become a central consideration now that many targeted cancers are managed as chronic or curable disease. Over his more than 40-year career at UCLA, his contributions have already earned him some of the highest honors in medicine and oncology, including the Lasker-DeBakey Clinical Medical Research Award, the Szent-Györgyi Prize for Progress in Cancer Research from the National Foundation for Cancer Research, the Sjöberg Prize from the Royal Swedish Academy of Sciences and Sweden’s Sjöberg Foundation, the American Cancer Society’s Medal of Honor for Clinical Research, and the Canada Gairdner International Award. The 2026 Albany Prize adds another landmark to a career that helped prove a radical idea: that decoding the molecular wiring of a tumor is the surest path to defeating it.

Subject of Research: Award of the 2026 Albany Prize to Dr. Dennis Slamon for discoveries in HER2-targeted and CDK4/6 inhibitor breast cancer therapy

Article Title: Dr. Dennis Slamon awarded the 2026 Albany Prize for developing lifesaving cancer treatments

Article References: Dr. Dennis Slamon awarded the 2026 Albany Prize for developing lifesaving cancer treatments. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Dennis Slamon, Albany Prize, HER2, Herceptin, breast cancer, targeted therapy, CDK4/6 inhibitors, palbociclib, ribociclib, UCLA, precision medicine, oncology